In settings like South Africa where routine second line DST is limited to FQN, SLI, and ethionamide (via mutations in the inhA promoter region on line probe assay) and with more than half of global MDR-TB cases estimated to be resistant to pyrazinamide [12], the strength of the BDQ backbone regimen is difficult to guarantee. Here, INHA is linked to tuberculosis.